PURPOSE: Trachoma is the leading infectious cause of blindness worldwide. Conjunctival scarring is initiated by recurrent Chlamydia trachomatis infection. However, disease progression to trichiasis occurs even in regions where chlamydial prevalence is currently low, which suggests that other factors, for example other bacterial infection, may also drive inflammation and scarring, particularly in the late stages of trachoma. This study was undertaken to investigate whether trachomatous trichiasis or conjunctival scarring are associated with increased prevalence of bacterial infection. METHODS: Within a case-control study design, individuals with trichiasis or conjunctival scarring (without trichiasis) were compared with normal matched control subjects. Subjects were examined for signs of trachoma. Conjunctival swab samples were collected for bacteriologic culture and C. trachomatis PCR. RESULTS: Recruited for the study were 121 trichiasis case-control pairs and 117 conjunctival scarring case-control pairs. Eyes with trichiasis were more frequently infected with bacteria (37%) than were normal control eyes (7%) (OR: 8.2; P < 0.001; 95% CI: 3.24-20.8). Bacterial infection was more common with increased trichiasis severity. In the conjunctival scarring case-control group, scarred eyes had slightly more bacterial infection (11%) than did normal control eyes (6%), although this was not significantly different (OR: 2.2; P = 0.144; 95% CI: 0.79-6.33). CONCLUSIONS: Trichiasis is associated with increased risk of bacterial infection, and there may be a similar trend in eyes with conjunctival scarring. Bacterial infection of the conjunctiva is associated with inflammation, which may result in progressive scarring. Prospective studies are needed to determine the contribution of bacterial infection to disease progression. Bacterial infection probably also contributes to the development of corneal opacification.
PURPOSE: Trachoma is the leading infectious cause of blindness worldwide. Conjunctival scarring is initiated by recurrent Chlamydia trachomatis infection. However, disease progression to trichiasis occurs even in regions where chlamydial prevalence is currently low, which suggests that other factors, for example other bacterial infection, may also drive inflammation and scarring, particularly in the late stages of trachoma. This study was undertaken to investigate whether trachomatous trichiasis or conjunctival scarring are associated with increased prevalence of bacterial infection. METHODS: Within a case-control study design, individuals with trichiasis or conjunctival scarring (without trichiasis) were compared with normal matched control subjects. Subjects were examined for signs of trachoma. Conjunctival swab samples were collected for bacteriologic culture and C. trachomatis PCR. RESULTS: Recruited for the study were 121 trichiasis case-control pairs and 117 conjunctival scarring case-control pairs. Eyes with trichiasis were more frequently infected with bacteria (37%) than were normal control eyes (7%) (OR: 8.2; P < 0.001; 95% CI: 3.24-20.8). Bacterial infection was more common with increased trichiasis severity. In the conjunctival scarring case-control group, scarred eyes had slightly more bacterial infection (11%) than did normal control eyes (6%), although this was not significantly different (OR: 2.2; P = 0.144; 95% CI: 0.79-6.33). CONCLUSIONS: Trichiasis is associated with increased risk of bacterial infection, and there may be a similar trend in eyes with conjunctival scarring. Bacterial infection of the conjunctiva is associated with inflammation, which may result in progressive scarring. Prospective studies are needed to determine the contribution of bacterial infection to disease progression. Bacterial infection probably also contributes to the development of corneal opacification.
Authors: Victor H Hu; Patrick Massae; Helen A Weiss; Caroline Chevallier; Jecinta J Onyango; Isaac A Afwamba; David C W Mabey; Robin L Bailey; Matthew J Burton Journal: Invest Ophthalmol Vis Sci Date: 2011-04-06 Impact factor: 4.799
Authors: Vicky Cevallos; John P Whitcher; Muluken Melese; Wondu Alemayehu; Elizabeth Yi; Jaya D Chidambaram; Scott Lee; Harsha Reddy; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan Journal: Invest Ophthalmol Vis Sci Date: 2012-08-07 Impact factor: 4.799
Authors: Emily W Gower; Shannath L Merbs; Beatriz E Munoz; Amir Bedri Kello; Wondu Alemayehu; Alemush Imeru; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2011-04-25 Impact factor: 4.799
Authors: Matthew J Burton; Robin L Bailey; David Jeffries; Saul N Rajak; Richard A Adegbola; Ansumana Sillah; David C W Mabey; Martin J Holland Journal: Invest Ophthalmol Vis Sci Date: 2010-03-17 Impact factor: 4.799
Authors: Matthew J Burton; Victor H Hu; Patrick Massae; Sarah E Burr; Caroline Chevallier; Isaac A Afwamba; Paul Courtright; Helen A Weiss; David C W Mabey; Robin L Bailey Journal: Invest Ophthalmol Vis Sci Date: 2011-07-29 Impact factor: 4.799
Authors: Matthew J Burton; Saul N Rajak; Julien Bauer; Helen A Weiss; Sonda B Tolbert; Alice Shoo; Esmail Habtamu; Alphaxard Manjurano; Paul M Emerson; David C W Mabey; Martin J Holland; Robin L Bailey Journal: Infect Immun Date: 2010-10-11 Impact factor: 3.441
Authors: Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Ansumana Sillah; Sandra Cohuet; Angels Natividad; Neal D E Alexander; David C W Mabey; Robin L Bailey Journal: PLoS Negl Trop Dis Date: 2010-10-05
Authors: Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams Journal: Hum Genet Date: 2008-05-30 Impact factor: 4.132
Authors: Victor H Hu; Helen A Weiss; Athumani M Ramadhani; Sonda B Tolbert; Patrick Massae; David C W Mabey; Martin J Holland; Robin L Bailey; Matthew J Burton Journal: Infect Immun Date: 2011-10-28 Impact factor: 3.441
Authors: Martin J Holland; David Jeffries; Michael Pattison; Gerit Korr; Alevtina Gall; Hassan Joof; Ahmed Manjang; Matthew J Burton; David C W Mabey; Robin L Bailey Journal: Invest Ophthalmol Vis Sci Date: 2010-04-07 Impact factor: 4.799